Unaudited standalone and consolidated financial results for the quarter and half year ended 30th September, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.1 pts more than Nifty Microcap 250 and 1.8 pts more than its Non Banking Financial Company (NBFC) peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Titan Securities Limited reported its Q2 and H1 FY26 (ended 30 Sept 2025) unaudited results, approved at the Board meeting on 11 November 2025. On a standalone basis, total revenue from operations grew about 33.7% year-on-year to Rs. 286.47 lakhs for H1 FY26, while standalone profit after tax jumped sharply to Rs. 33.19 lakhs from Rs. 4.94 lakhs in H1 FY25. Consolidated net profit after tax (including share of associates) was Rs. 651.81 lakhs for H1 FY26 vs Rs. 599.13 lakhs a year earlier, with associates Titan Biotech and Peptech Biosciences contributing Rs. 594.19 lakhs as share of profit. Standalone EPS for H1 FY26 stood at Rs. 0.13, while consolidated diluted EPS was Rs. 2.39. The statutory auditor (A N S K & Associates) issued an unqualified limited review report with no qualifications.
Headline standalone revenue and profit growth look strong, but the bulk of consolidated earnings comes from associates rather than the parent's core operations, so investors should track associate performance closely. Operating cash flow remained marginally negative at Rs. (1.97) lakhs in H1 FY26, which is a watch point despite being an improvement over last year.